Cho‐Ming Loi - Concepedia

Author

Cho‐Ming Loi

Pfizer (United States)

Also Known As

C M Loi, Cho-Ming Loi, Cho‐Ming Loi

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)University of Washington Idaho State University Applied Dynamics International (United States)Boise VA Medical Center

About

Cho‐Ming Loi is an author at Pfizer (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	650
2	Health Sciences	4	4	314
3	Biochemistry	3	3	332
4	Applied Physiology	1	1	75
5	Endocrinology	1	1	31

Cho‐Ming Loi

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth Brion W. Murray, Chuangxing Guo, Joseph Piraino, Proceedings of the National Academy of Sciences	2010	318
Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor Andrea J. Gonzales, Kenneth E. Hook, Irene W. Althaus, Molecular Cancer Therapeutics	2008	220
Assessment of Three Human in Vitro Systems in the Generation of Major Human Excretory and Circulating Metabolites Deepak Dalvie, R. Scott Obach, Ping Kang, Chemical Research in Toxicology Circulating MetabolitesMetabolomic ProfilingSecondary MetaboliteMetabolic ModelVitro Systems	2009	183
In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration Yvonne S. Lin, G. Lockwood, Martin A. Graham, Pharmacogenetics	2001	134
Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration Alan Brown, Tage Carlson, Cho‐Ming Loi, Cancer Chemotherapy and Pharmacology Intravenous AdministrationPharmacological StudyMedicineImmunologyToxicokinetic Evaluation	2006	124
Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans Susan Hurst, Cho‐Ming Loi, Joanne Brodfuehrer, Expert Opinion on Drug Metabolism & Toxicology Drug Oral BioavailabilityTherapeutic ResponsePharmacokineticsPharmacological StudyOral Drug Bioavailability	2007	117
Roles of Exercise and Pharmacokinetics in Cerivastatin-Induced Skeletal Muscle Toxicity Jennifer L. Seachrist, Cho‐Ming Loi, Mark G. Evans, Toxicological Sciences Cardiovascular ToxicityMuscle TissueMuscle FunctionKinesiologyMuscle Injury	2005	75
Cross-Species Comparison of the Metabolism and Excretion of Zoniporide: Contribution of Aldehyde Oxidase to Interspecies Differences Deepak Dalvie, Chenghong Zhang, Wei‐Chao Chen, Drug Metabolism and Disposition	2009	71
Physiologically Based Pharmacokinetic Modeling of Palbociclib Yanke Yu, Cho‐Ming Loi, Justin Hoffman, The Journal of Clinical Pharmacology	2016	62
Atorvastatin Glucuronidation Is Minimally and Nonselectively Inhibited by the Fibrates Gemfibrozil, Fenofibrate, and Fenofibric Acid Theunis C. Goosen, Jonathan Bauman, John A. Davis, Drug Metabolism and Disposition	2007	54

Page 1